
Opinion|Videos|June 21, 2024
Expert Insights: Biomarker Evaluation and Timing in Management of Patients with mUC
Author(s)Pedro Barata, MD, MSc, FACP
A leading expert in the field shares their insights on the specific biomarkers they evaluate, such as Trop2, FGFR, and PD-L1, and the optimal timing for conducting these tests based on their clinical experience and patient management strategies.
Advertisement
- What biomarkers do you routinely test for (e.g. Trop2, FGFR, PD-L1) and at what point in the disease course? Discuss the importance of earlier vs later testing and the platforms used.
Advertisement
Related to this article

Updated LEGEND trial data show durable responses with detalimogene in BCG-unresponsive NMIBC, supporting a planned BLA submission by year-end 2026.

The FDA issued a complete response letter to the biologics license application for ivonescimab for use in combination with chemotherapy in EGFR-mutated NSCLC.

Crossover to bezuclastinib plus sunitinib after progression on sunitinib improved PFS and responses in GIST in phase 3 PEAK, with no new safety signals.

Arvind Dasari, MD, MS, explains how to sequence radioligand therapy, cabozantinib, and everolimus in well-differentiated neuroendocrine tumors.

A survey of US veterans with non-muscle invasive bladder cancer identifies barriers to treatment access, care coordination challenges, and gaps in patient education.

The perioperative regimen improved event-free and overall survival in the phase 3 VOLGA trial, offering a new option for patients with muscle-invasive bladder cancer who cannot receive or decline cisplatin.

Ravi Parikh, MD, MPP, discusses the future of oncology practice, including real-world data, patient engagement, emerging technologies, and policy priorities shaping cancer care.
Advertisement
Advertisement
Trending on Targeted Onc
1
FDA Does Not Approve Ivonescimab for EGFR-Mutant NSCLC
2
Dr Dasari on Sequencing RLT, Cabozantinib, and Everolimus in NETs
3
Crossover to Bezuclastinib Plus Sunitinib Improves Disease Control in Pretreated GIST
4
FDA Approves Durvalumab-EV Combo, Expanding MIBC Treatment Options
5
